References
- Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. [ cited 2012 Jan];87(1):78–88. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Hematol+2012%3B+87%3A+78-88 doi: 10.1002/ajh.22237
- Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. [ cited 2013 Feb 7];121(6):884–892. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Improving+overall+survival+and+overcoming+adverse+prognosis+in+the+treatment+of+cytogenetically+high-risk+multiple+myeloma doi: 10.1182/blood-2012-05-432203
- Pulte D, Redaniel MT, Lowry L, et al. Age disparities in survival from lymphoma and myeloma: a comparison between US and England. Br J Haematol. [ cited 2014 Jun];165(6):824–831. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Age+disparities+in+survival+from+lymphoma+and+myeloma%3A+a+comparison+between+US+and+England doi: 10.1111/bjh.12837
- Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. [ cited 2014 Aug 20];32(24):2531–2540. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Multiple+Myeloma+in+the+Older+Adult%3A+Better+Prospects%2C+More+Challenges doi: 10.1200/JCO.2014.55.1028
- Uttervall K, Duru AD, Lund J, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. [ cited 2014 Jul 8];9(7):e101819. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=The+use+of+novel+drugs+can+effectively+improve+response%2C+delay+relapse+and+enhance+overall+survival+in+multiple+myeloma+patients+with+renal+impairment doi: 10.1371/journal.pone.0101819
- Laubach JP, Voorhees PM, Hassoun H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. [ cited 2014 Feb];7(1):97–111. Available at http://www.ncbi.nlm.nih.gov/pubmed/24471924 doi: 10.1586/17474086.2014.882764
- Kropff M, Baylon HG, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. [ cited 2012 May];97(5):784–791. Available at http://www.ncbi.nlm.nih.gov/pubmed/22133776 doi: 10.3324/haematol.2011.044271
- Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. [ cited 2014 Mar 6];123(10):1461–1469. Available at http://www.ncbi.nlm.nih.gov/pubmed/24429336 doi: 10.1182/blood-2013-07-517276
- Zago M, Oehrlein K, Rendl C, et al. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Ann Hematol. [ cited 2014 Dec];93(12):1993–1999. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Lenalidomide+in+relapsed+and+refractory+multiple+myeloma+disease%3A+feasibility+and+benefits+of+long-term+treatment doi: 10.1007/s00277-014-2149-2
- Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. [ cited 2014 Mar 20];123(12):1826–1832. Available at http://www.ncbi.nlm.nih.gov/pubmed/24421329 doi: 10.1182/blood-2013-11-538835
- Chanan-Khan AA, Lonial S, Weber D, et al. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. Int J Hematol. [ cited 2012 Aug];96(2):254–262. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Int+J+Hematol+2012%3B+96%3A+254-262 doi: 10.1007/s12185-012-1125-7
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. [ cited 2006 Sep];20(9):1467–1473. Available at http://www.ncbi.nlm.nih.gov/pubmed/16855634 doi: 10.1038/sj.leu.2404284
- Romano A, Conticello C, Cavalli M, et al. Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int. [ cited 2014];2014:456037. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Salvage+therapy+of+multiple+myeloma%3A+the+new+generation+drugs.+Biomed+Res+Int+2014%3B+2014%3A+456037
- Richardson P, Mitsiades C, Laubach J, et al. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. [ cited 2010 Jun 15];4:215–245. Available at http://www.ncbi.nlm.nih.gov/pubmed/20694078
- Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. [ cited 2007 Nov 22];357(21):2133–2142. Available at http://www.ncbi.nlm.nih.gov/pubmed/18032763 doi: 10.1056/NEJMoa070596
- João C, Coelho I, Costa C, et al. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma – real life experience of a tertiary cancer center. Ann Hematol. [ cited 2015 Jan];94(1):97–105. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Efficacy+and+safety+of+lenalidomide+in+relapse%2Frefractory+multiple+myeloma-Real+life+experience+of+a+tertiary+cancer+center doi: 10.1007/s00277-014-2164-3
- Shen M, Wang J, Yang G, et al. Effectiveness of lenalidomide-based chemotherapy on 25 patients with multiple myeloma. J Leukemia Lymphoma. [ cited 2010];19(7):401–403. Available at http://d.wanfangdata.com.cn/Periodical/bxblbl201007006
- Zhong Y. Progress in the treatment of lenalidomide on relapsed and refractory multiple myeloma. J Mod Med Health. [ cited 2013];29(10):1514–1517. Available at http://www.xdyyws.com/paper.aspx?id=10966
- Spencer A, Yoon SS, Harrison SJ, et al. Novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. [ cited 2014 Oct 2];124(14):2190–2195. Available at http://www.ncbi.nlm.nih.gov/pubmed/?term=Novel+AKT+inhibitor+afuresertib+shows+favorable+safety%2C+pharmacokinetics%2C+and+clinical+activity+in+multiple+myeloma doi: 10.1182/blood-2014-03-559963
- Castelli R, Orofino N, Losurdo A, et al. Choosing treatment options for patients with relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther. [ cited 2014 Feb];14(2):199–215. Available at http://www.ncbi.nlm.nih.gov/pubmed/24329153 doi: 10.1586/14737140.2014.863153